Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference
In: Business Wire (English), 2023-12-14
Online
Zeitungsartikel
Zugriff:
OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform,the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society. The Company presented an overview of OmnidAb and its functionality to industry leaders and prospective customers today in a presentation by Christine Vuong, Ph.D., Senior Scientist, titled “Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding.” [ABSTRACT FROM PUBLISHER]
Titel: |
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference
|
---|---|
Autor/in / Beteiligte Person: | OmniAb, Inc. |
Zeitschrift: | Business Wire (English), 2023-12-14 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|